These data are important for treatment considerations in patients with IDH-mutant astrocytomas, as they indicate that temozolomide therapy can induce MMR mutation and result in worse outcomes in a subset of these patients, but also suggests a role for immune checkpoint inhibitors to inform potential treatment strategies, although there is disagreement on the efficacy of immunotherapy in the setting of hypermutant gliomas.19,47–49. The gene discussed is IDH1; the disease is central nervous system cancer.